Key facts
- This page summarizes Mark G. Edwards's Form 4 filing for ACELRX PHARMACEUTICALS INC (TLPH).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 Jun 2021, 17:23.
Mark G. Edwards - 17 Jun 2021 Form 4 Insider Report for ACELRX PHARMACEUTICALS INC (TLPH)
- Reporting relationship
- Director
- Issuer ticker
- TLPH
- Reported as of
- 17 Jun 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Martha Adler, Attorney-In-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Mark G. Edwards filed Form 4 for ACELRX PHARMACEUTICALS INC (TLPH) on 17 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACRX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +10,000
- Change %
- +4%
- Price
- $0.000000
- Shares after
- 261,250
- Date
- 17 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACRX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- Price
- $0.000000
- Shares after
- 20,000
- Date
- 17 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $1.41
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company.
Footnote F3
100% of the option shares subject to the option shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company.